NCT05481619View on ClinicalTrials.gov

Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions

Ulcerative Colitis

Interventions

DRUG

Vedolizumab

"Recommended dose in patients with UC: 300 mg intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter.~Discontinue vedolizumab at week 14 in patients who do not show treatment benefit."

Trial Locations (1)

310000

RECRUITING

Second Affiliated Hospital Zhejiang University School of Medicine, Zhengzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER